Long-term outcomes and pretreatment immune profiling of perioperative toripalimab plus FLOT in gastric or gastroesophageal junction adenocarcinoma: a phase II trial

Long-term outcomes after perioperative immunochemotherapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma remain incompletely characterised. In this single-arm phase II trial (NCT04354662), 51 patients with locally advanced G/GEJ received toripalimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel before surgery with postoperative treatment were enrolled. The reported co-primary endpoints were primary-tumour pathological complete response and 3-year DFS. With median follow-up of 63.1 months, primary-tumour complete response was 19.6% (10/51), whereas nodal-inclusive ypT0N0 response was 13.7% (7/51). Three-year DFS was 52.9% (95% CI, 38.5%-65.5%), 5-year OS was 59.0% (42.9%-71.9%). Grade ≥3 reported treatment-related adverse events occurred in 72.5% of patients. Pretreatment biopsies from 24 patients underwent multiplex immunofluorescence. Higher stromal CD3 positivity was nominally associated with longer survival after median dichotomization, but continuous-variable associations were nonsignificant and no feature survived false-discovery-rate correction. Findings support independent investigation of stromal CD3 positivity but establish neither comparative benefit nor biomarker validity.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11665269/v1
Primary Topic
Gastric Cancer Management and Outcomes
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Long-term outcomes and pretreatment immune profiling of perioperative toripalimab plus FLOT in gastric or gastroesophageal junction adenocarcinoma: a phase II trial

Fenglin Zang, Jingyu Deng, Yi Ba, Peng Ren et al.
Research Square
Gastric Cancer Management and Outcomes
preprint

Long-term outcomes and pretreatment immune profiling of perioperative toripalimab plus FLOT in gastric or gastroesophageal junction adenocarcinoma: a phase II trial

Fenglin Zang, Jingyu Deng, Yi Ba, Peng Ren, Ting Deng, Feixue Wang, Yue Song, Tao Ning, Ming Bai, Shaohua Ge, Hongli Li, Yuchong Yang, Jiayu Zhang, Si Yiran, Likun Zhou, Rui Liu, Jing-Jing Duan, Xiao-Qing Li, Le Zhang, Fuliang Cao, Yansha Sun, Li-Yan Zhou, Yi-Lin Deng
preprint en

Abstract

Long-term outcomes after perioperative immunochemotherapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma remain incompletely characterised. In this single-arm phase II trial (NCT04354662), 51 patients with locally advanced G/GEJ received toripalimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel before surgery with postoperative treatment were enrolled. The reported co-primary endpoints were primary-tumour pathological complete response and 3-year DFS. With median follow-up of 63.1 months, primary-tumour complete response was 19.6% (10/51), whereas nodal-inclusive ypT0N0 response was 13.7% (7/51). Three-year DFS was 52.9% (95% CI, 38.5%-65.5%), 5-year OS was 59.0% (42.9%-71.9%). Grade ≥3 reported treatment-related adverse events occurred in 72.5% of patients. Pretreatment biopsies from 24 patients underwent multiplex immunofluorescence. Higher stromal CD3 positivity was nominally associated with longer survival after median dichotomization, but continuous-variable associations were nonsignificant and no feature survived false-discovery-rate correction. Findings support independent investigation of stromal CD3 positivity but establish neither comparative benefit nor biomarker validity.

Research Square
Tianjin Medical University Cancer Institute and Hospital (CN), State Key Laboratory of Oncogene and Related Genes (CN), First Hospital of China Medical University (CN), Tianjin Medical University (CN), Nanjing University (CN)
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon